Replies to post #25 on Gamida Cell Ltd (GMDAQ)

[Spideyboy]

I guess no-one will mind us talking a little further about off-topic companies on this board :)

Thanks for raisin that and just read the article and it does a good job of covering the key points. Interesting he has some of his grammar at different points in time. He clearly knows about the RHB-106 return to RedHill that just happened, but apparently doesn't know that Aemcolo was already officially launched earlier in Q42019.

Something I find interesting too between RedHill and Protalix is that, RedHill has a product for IBS (Bekinda) and Crohn's (RHB-104), where Protalix in OPRX-106 also has a product to tackle both of these. Perhaps they could share the market if RedHill goes for less severe patients, and Protalix goes for more severe patients, particularly as inside OPRX-106 is the most expensive go-to product, anti-TNFalpha. I expect very good things from OPRX-106, and especially if given to patients longer than the Phase II trial of 8 weeks.

That they reached 67% Clinical Response and 28% Complete Remission, in 8 weeks is very well done. And with the added benefit of no real adverse events and the elimination of systemic exposure of the drug. Looking forward to the next 3-4 years. Hoping that's all I'll need :)